← Eichor
Study identifier: NCT05992831 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Transcranial Magnetic Stimulation for MCI

Condition: Mild Cognitive Impairment · Depression  ·  Sponsor: Medical University of South Carolina

PhaseNA
Planned participants60
Who can joinAll sexes, 60 Years to 85 Years
Healthy volunteersNo

About this study

The goal of this phase II study is to establish the dose-response curves of a safe and clinically feasible non-invasive brain stimulation technique (accelerated Transcranial Magnetic Stimulation (TMS)) to improve both depression and cognitive function in Mild Cognitive Impairment (MCI) patients with comorbid depression. It is known that TMS can effectively treat depression. Identifying the right dose of accelerated TMS in MCI patients is necessary prior to designing subsequent trials to determine efficacy. These results will inform future clinical trials of accelerated TMS for MCI, with the long-term goal of developing an efficacious treatment to prevent dementia.

This description comes directly from the study's public registry record.

Talk to the study team

Andreana Benitez, PhD  ·  843-876-2479  ·  benitez@musc.edu

Katrina Madden, MBA  ·  843-792-9186  ·  maddenka@musc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Medical University of South CarolinaCharleston, South Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05992831